Corneal Endothelial Cell Transplant Market Size, Trends and Forecast 2024-2032

According to FutureWise analysis the market for Corneal Endothelial Cell Transplant in 2023 was US$ 303.2 million, and is expected to reach US$ 630 million by 2031 at a CAGR of 9.30%.

A corneal transplant is a technique for replacing a damaged or diseased cornea that may have developed as a result of an eye accident or an eye condition. The two most common transplant procedures worldwide are penetrating keratoplasty (full thickness cornea transplant) and endothelial keratoplasty (back layer cornea transplant). Vision blurring due to a sick cornea indicates the need for a corneal transplant.

The monolayer of cells forming the human corneal endothelium is critical to the maintenance of corneal transparency and is not known to regenerate in vivo. Hence, the roughly 150,000 corneal transplants that are performed each year are most frequently attributed to the malfunctioning of these cells. Even though current corneal transplantation has a success rate of over 90% after a year, the longer-term results are less encouraging, with a success rate of only about 70% after five years. Nonimmunologic graft failure and allograft endothelial rejection are the main problems. Moreover, fewer corneal transplants can be performed because of the severe global corneal donor shortage. Human corneal endothelial cells (HCECs) can now be grown in vitro thanks to advances in our understanding of corneal endothelial cell biology, opening up new possibilities for the creation of novel tissue-engineered human corneal endothelium.

Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Corneal-Endothelial-Cell/15193